Johnson & Johnson $JNJ Shares Acquired by Trek Financial LLC

Trek Financial LLC lifted its stake in Johnson & Johnson (NYSE:JNJ) by 204.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 11,529 shares of the company’s stock after purchasing an additional 7,738 shares during the period. Trek Financial LLC’s holdings in Johnson & Johnson were worth $2,138,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in JNJ. SOA Wealth Advisors LLC. boosted its stake in shares of Johnson & Johnson by 0.7% during the 3rd quarter. SOA Wealth Advisors LLC. now owns 7,392 shares of the company’s stock worth $1,371,000 after acquiring an additional 53 shares in the last quarter. Ethos Financial Group LLC boosted its position in Johnson & Johnson by 0.6% during the third quarter. Ethos Financial Group LLC now owns 9,110 shares of the company’s stock worth $1,689,000 after purchasing an additional 53 shares in the last quarter. Heritage Oak Wealth Advisors LLC boosted its position in Johnson & Johnson by 3.5% during the third quarter. Heritage Oak Wealth Advisors LLC now owns 1,639 shares of the company’s stock worth $304,000 after purchasing an additional 55 shares in the last quarter. Lifestyle Asset Management Inc. increased its position in shares of Johnson & Johnson by 3.4% in the third quarter. Lifestyle Asset Management Inc. now owns 1,683 shares of the company’s stock valued at $312,000 after buying an additional 56 shares in the last quarter. Finally, Wynn Capital LLC increased its position in shares of Johnson & Johnson by 0.4% in the third quarter. Wynn Capital LLC now owns 15,930 shares of the company’s stock valued at $2,954,000 after buying an additional 57 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on JNJ. Barclays increased their price objective on shares of Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 30th. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a research report on Sunday. The Goldman Sachs Group reiterated a “buy” rating and set a $250.00 target price on shares of Johnson & Johnson in a report on Thursday. Argus boosted their price target on Johnson & Johnson from $210.00 to $240.00 in a report on Friday. Finally, Raymond James Financial increased their price objective on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday, October 15th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $226.18.

Johnson & Johnson Price Performance

JNJ stock opened at $221.54 on Tuesday. The stock has a market capitalization of $533.76 billion, a price-to-earnings ratio of 20.05, a price-to-earnings-growth ratio of 2.14 and a beta of 0.34. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 52-week low of $141.50 and a 52-week high of $222.17. The stock’s fifty day simple moving average is $208.79 and its 200-day simple moving average is $189.84.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 21st. The company reported $2.46 earnings per share for the quarter, hitting the consensus estimate of $2.46. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The firm had revenue of $24.56 billion for the quarter, compared to the consensus estimate of $24.14 billion. During the same period in the prior year, the business posted $2.04 earnings per share. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. Equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Tuesday, February 24th will be issued a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date is Tuesday, February 24th. Johnson & Johnson’s payout ratio is presently 47.06%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.